» Articles » PMID: 25003632

Effects of Acute Administration of Selective Serotonin Reuptake Inhibitors on Sympathetic Nerve Activity

Overview
Date 2014 Jul 9
PMID 25003632
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Serotonergic mechanisms have an important function in the central control of circulation. Here, the acute effects of three selective serotonin (5-HT) reuptake inhibitors (SSRIs) on autonomic and cardiorespiratory variables were measured in rats. Although SSRIs require 2-3 weeks to achieve their full antidepressant effects, it has been shown that they cause an immediate inhibition of 5-HT reuptake. Seventy male Wistar rats were anesthetized with urethane and instrumented to record blood pressure, heart rate, renal sympathetic nerve activity (RSNA), and respiratory frequency. At lower doses, the acute cardiovascular effects of fluoxetine, paroxetine and sertraline administered intravenously were insignificant and variable. At middle and higher doses, a general pattern was observed, with significant reductions in sympathetic nerve activity. At 10 min, fluoxetine (3 and 10 mg/kg) reduced RSNA by -33 ± 4.7 and -31 ± 5.4%, respectively, without changes in blood pressure; 3 and 10 mg/kg paroxetine reduced RSNA by -35 ± 5.4 and -31 ± 5.5%, respectively, with an increase in blood pressure +26.3 ± 2.5; 3 mg/kg sertraline reduced RSNA by -59.4 ± 8.6%, without changes in blood pressure. Sympathoinhibition began 5 min after injection and lasted approximately 30 min. For fluoxetine and sertraline, but not paroxetine, there was a reduction in heart rate that was nearly parallel to the sympathoinhibition. The effect of these drugs on the other variables was insignificant. In conclusion, acute peripheral administration of SSRIs caused early autonomic cardiovascular effects, particularly sympathoinhibition, as measured by RSNA. Although a peripheral action cannot be ruled out, such effects are presumably mostly central.

Citing Articles

Sex differences in Black Veterans with PTSD: women versus men have higher sympathetic activity, inflammation, and blunted cardiovagal baroreflex sensitivity.

Fonkoue I, Tahsin C, Jones T, King K, Tahmin C, Jeong J Clin Auton Res. 2023; 33(6):757-766.

PMID: 37898568 PMC: 11256876. DOI: 10.1007/s10286-023-00995-1.


Serotonergic Modulation of Neurovascular Transmission: A Focus on Prejunctional 5-HT Receptors/Mechanisms.

Gonzalez-Hernandez A, Marichal-Cancino B, MaassenVanDenBrink A, Villalon C Biomedicines. 2023; 11(7).

PMID: 37509503 PMC: 10377335. DOI: 10.3390/biomedicines11071864.


The results of a unique dietary supplement (nutraceutical formulation) used to treat the symptoms of long-haul COVID.

Gaylis N, Kreychman I, Sagliani J, Mograbi J, Gabet Y Front Nutr. 2022; 9:1034169.

PMID: 36386945 PMC: 9641293. DOI: 10.3389/fnut.2022.1034169.


Is Fluoxetine Good for Subacute Stroke? A Meta-Analysis Evidenced From Randomized Controlled Trials.

Liu G, Yang X, Xue T, Chen S, Wu X, Yan Z Front Neurol. 2021; 12:633781.

PMID: 33828519 PMC: 8019826. DOI: 10.3389/fneur.2021.633781.


Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake.

Blom T, Meinsma R, Rutgers M, Buitenhuis C, Dekken-Van den Burg M, van Kuilenburg A EJNMMI Res. 2020; 10(1):78.

PMID: 32642907 PMC: 7343696. DOI: 10.1186/s13550-020-00662-w.


References
1.
Pires J, Bonikovski V, Futuro-Neto H . Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice. Braz J Med Biol Res. 2005; 38(12):1867-72. DOI: 10.1590/s0100-879x2005001200015. View

2.
Angulo J, Bischoff E, Gabancho S, Cuevas P, Saenz de Tejada I . Vardenafil reverses erectile dysfunction induced by paroxetine in rats. Int J Impot Res. 2003; 15(2):90-3. DOI: 10.1038/sj.ijir.3900950. View

3.
Medow M, Stewart J, Sanyal S, Mumtaz A, Sica D, Frishman W . Pathophysiology, diagnosis, and treatment of orthostatic hypotension and vasovagal syncope. Cardiol Rev. 2007; 16(1):4-20. DOI: 10.1097/CRD.0b013e31815c8032. View

4.
Belmaker R, Agam G . Major depressive disorder. N Engl J Med. 2008; 358(1):55-68. DOI: 10.1056/NEJMra073096. View

5.
Owens M, Morgan W, Plott S, Nemeroff C . Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1998; 283(3):1305-22. View